In the genome sequencing space, the stock highlighted in today’s article may not be the best stock – yet. As the author details, however, “when it comes to shareholder returns in the past year, [it] was one of the top performers, rewarding investors lavishly.” In fact, this biotechnology company, which develops gene sequencing systems, has seen its stock surge around 1700% over the past year – and its monster run may be set to continue. For more, CLICK HERE.
This Genome Sequencing Stock’s Monster Run May Be Far From Over
- by RobH
![](https://www.hotstockanalyst.com/wp-content/uploads/2021/02/2021-02-18-08_30_44-Free-stock-photo-of-analysis-biology-biotech.png)
Tags:BiosciencesBiotechnology InvestmentsGenome Sequencing StocksInvestinvestorsShareholder ReturnsShareholdersStock MarketSurging Stocks